Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis

Brain Research

Volumn 1310, Issue , 2010, Pages 154-161

  Zagon, Ian S ^a   Rahn, Kristen A ^a   Bonneau, Robert H ^a   Turel, Anthony P ^a   McLaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmune Diseases; Experimental Autoimmune Encephalomyelitis; Multiple Sclerosis; Opioid; Opioid Growth Factor; Opioid Growth Factor Receptor

Indexed keywords

METENKEPHALIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; OPIATE RECEPTOR; SODIUM CHLORIDE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BEHAVIOR CHANGE; C57BL 6 MOUSE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; DISEASE SEVERITY; DNA SYNTHESIS; DRUG EFFECT; FEMALE; IMMUNOHISTOCHEMISTRY; LUMBAR SPINAL CORD; LYMPHOCYTE CULTURE; MOUSE; NERVE CELL LESION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REMISSION; SPLEEN LYMPHOCYTE; T LYMPHOCYTE;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENKEPHALIN, METHIONINE; FEMALE; GLYCOPROTEINS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEUROTRANSMITTER AGENTS; PEPTIDE FRAGMENTS; RECEPTORS, OPIOID; SPINAL CORD; TIME FACTORS;

ANIMALIA; MUS;

EID: 73149104142     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.11.026     Document Type: Article

References (43)

1. Ayers M.M., Hazelwood L.J., Catmull D.V., Wang D., McKormack O., Bernard C.C., and Orian J.M. Early glial responses in murine models of multiple sclerosis. Neurochem. Int. 45 (2004) 409-419
2. Bannerman P., and Hahn A. Enhanced visualization of axonopathology in EAE using thy1-YFP transgenic mice. J. Neurol. Sci. 260 (2007) 23-32
3. Bannerman P., Hahn A., Soulika A., Gallo V., and Pleasure D. Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia. Glia 55 (2007) 57-64
4. Blebea J., Mazo J.E., Kihara T.K., Vu J.-H., McLaughlin P.J., Atnip R.G., and Zagon I.S. Opioid growth factor modulates angiogenesis. J. Vasc. Surg. 32 (2000) 364-373
5. WAF1/CIP1 pathways to restrict normal cell proliferation. Mol. Biol. Cell 20 (2009) 319-327
6. Cheng F., McLaughlin P.J., Verderame M.F., and Zagon I.S. Dependence on nuclear localization signals of the opioid growth factor receptor (OGFr) in the regulation of cell proliferation. Exp. Biol. Med. 234 (2009) 532-541
7. Dass C., and Mahalakshmi P. Phosphorylation of enkephalins enhances their proteolytic stability. Life Sci. 58 (1996) 1039-1045
8. Donahue R.N., McLaughlin P.J., and Zagon I.S. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am. J. Physiol., Regul. Integr. Comp. Physiol. 296 (2009) R1716-R1725
9. El Behi M., Dubucquoi S., Lefranc D., Zephir H., De Seze J., Vermersch P., and Prin L. New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Lett. 96 (2005) 11-26
10. Encinas J.A., Lees M.B., Sobel R.A., Symonowicz C., Greer J.M., Shovlin C.L., Weiner H.L., Seidman C.E., Seidman J.G., and Kuchroo V.K. Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice. J. Immunol. 157 (1996) 2186-2192
11. Fontoura P., Steinman L., and Miller A. Emerging therapeutic targets in multiple sclerosis. Curr. Opin. Neurol. 19 (2006) 260-266
12. Forte M., Gold B.G., Marracci G., Chaudhary P., Basso E., Johnsen D., Yu X., Fowlkes J., Rahder M., Stem K., Bernardi P., and Bourdette D. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 7558-7563
13. Gold R., Linington C., and Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129 (2006) 1953-1971
14. Gutstein H.B., and Akil H. Opioid Analgesics. The Pharmacological Basis of Therapeutics. 10th ed (2001), McGraw Hill, New York 569 -XXXX
15. Jankovic B.D. Enkephalins and immune inflammatory reactions. Acta Neurol (Napoli) 13 (1991) 433-441
16. Jankovic B.D., and Maric D. Enkephalins and autoimmunity: differential effect of methionine-enkephalin on experimental allergic encephalomyelitis in Wistar and Lewis rats. J. Neurosci. Res. 18 (1987) 88-94
17. Jankovic B.D., and Maric D. Methionine-enkephalin inhibits adoptive transfer of experimental allergic encephalomyelitis in the rat. Int. J. Neurosci. 51 (1990) 197-199
18. Kamphuis S., Eriksson F., Kavelaars A., Zijlstra J., van de Pol M., Kuis W., and Jeijnen C.J. Role of endogenous pro-enkephalin A-derived peptides in human T cell proliferation and monocyte IL-6 production. J. Neuroimmunol. 84 (1998) 53-60
19. Klocek M.S., Sassani J.W., McLaughlin P.J., and Zagon I.S. Topically applied naltrexone restores corneal reepithelialization in diabetic rats. J. Ocular Pharmacol. Therap. 23 (2007) 89-102
20. Lutton J.D., Winston R., and Rodman T.C. Multiple sclerosis: etiological mechanisms and future directions. Exp. Biol. Med. 229 (2004) 12-20
21. MacNamara K.C., Chua M.M., Nelson P.T., Shen H., and Weiss S.R. Increased epitope-specific CD8+ T cells prevent murine coronavirus spread to the spinal cord and subsequent demyelination. J. Virol. 79 (2005) 3370-3381
22. Milicevic I., Pekovic S., Subasic S., Mostarica-Stojkovic M., Stosic-Grujicic S., Medic-Milacevic L., Pejanovic V., Rakic L., and Stojiljkovic M. Ribavarin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats. J. Neurosci. Res. 72 (2003) 268-278
23. Rizvi S.A., and Agius M.A. Current approved options for treating patients with multiple sclerosis. Neurology 63 (2004) S8-S14
24. Sharp B.M. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav. Immun. 20 (2006) 9-14
25. Sidman R.L. Atlas of the mouse brain and spinal cord (1979), Harvard University Press, Cambridge
26. Smith J.P., Ahmad M., Conter R., Bingaman S., Harvey H., Mauger D., Demers L., McLaughlin P.J., Stanley S., and Zagon I.S. Treatment of advanced pancreatic cancer with opioid growth factor. Anti-Cancer Drugs 15 (2004) 203-209
27. Stambuk N., Brinar V., Stambuk V., Svoboda-Beusan I., Rabatic S., Mazuran R., Marusic-Dellamarina B., Brzovic Z., Zurak N., Marotti T., Sverko V., Rudolf M., Martinic R., Karaman K., Masic N., Sucic Z., and Pokric B. Peptid-M (Lupex) immunotherapy in multiple slcerosis, optic neuritis and uveitis. Int. J. Thymol. 5 (1997) 448-464
28. Steinman L., and Zamvil S.S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26 (2005) 565-571
29. Stichel C.C., and Luebbert H. Inflammatory processes in the aging mouse brain. Neurobiol. Aging 280 (2007) 1507-1521
30. Suen W.E., Bergman C.M., Hjelmstrom P., and Ruddle N.H. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J. Exp. Med. 186 (1997) 1233-1240
31. Tsunoda I., Wada Y., Libbey J.E., Cannon T.S., Whitby F.G., and Fujinami R.S. Prolonged gray matter disease without demyelination caused by Theiler's murine encephalomyelitis virus with a mutation in VP2 puff B. J. Virol. 75 (2001) 7494-7505
32. Veljic J., Maric D., and Jankovic B.D. Changes of experimental allergic encephalomyelitis by methionine-enkephalin injected into lateral ventricles of the rat brain. Int. J. Neurosci. 59 (1991) 81-89
33. Wang Y., Van Bockstaele E.J., and Liu-Chen L.Y. In vivo trafficking of endogenous opioid receptors. Life Sci. 83 (2008) 693-699
34. Wollemann M., and Benyhe S. Non-opioid actions of opioid peptides. Life Sci. 75 (2004) 257-270
35. Zagon I.S., Gibo D.M., and McLaughlin P.J. Ontogeny of zeta (ζ), the opioid growth factor receptor, in the rat brain. Brain Res. 596 (1992) 149-156
36. Zagon I.S., and McLaughlin P.J. Naltrexone modulates tumor response in mice with neuroblastoma. Science 221 (1983) 671-673
37. Zagon I.S., and McLaughlin P.J. Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer. Life Sci. 35 (1984) 409-416
38. Zagon I.S., and McLaughlin P.J. Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors. Brain Res. 480 (1989) 16-28
39. 5]-enkephalin to acute opioid antagonist (naltrexone) exposure. Mol. Brain Res. 33 (1995) 111-120
40. Zagon I.S., Rahn K.A., Turel A.P., and McLaughlin P.J. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp. Biol. Med. 234 (2009) 1383-1392
41. Zagon I.S., Verderame M.F., and McLaughlin P.J. The biology of the opioid growth factor receptor (OGFr). Brain Res. Rev. 38 (2002) 351-376
42. Zahwa H., Yorty J.L., and Bonneau R.H. Elevated maternal corticosterone during lactation hinders the neonatal adaptive immune response to herpes simplex virus (HSV) infection. Brain Behav. Immun. 22 (2008) 339-353
43. Ziaber J., Baj Z., Pasnik J., Chmielewski H., and Tchorzewski H. Increased expression of neutral endopeptidase (NEP) and aminopeptidase N (APN) on peripheral blood mononuclear cells in patients with multiple sclerosis. Immunol. Lett. 71 (2000) 127-129